Stocks Ensnare on Profitability Ratio: Synergy Pharmaceuticals (NASDAQ:SGYP), Tonix Pharmaceuticals Holding (NASDAQ:TNXP)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) also making a luring appeal, share price swings at $6.67 with percentage change of 1.14% in most recent trading session.

Synergy Pharmaceuticals Inc. (SGYP) reported positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients suffering from irritable bowel syndrome with constipation (IBS-C). The company’s share price surged 21.7% following the announcement.

Preliminary analysis of data from the trial indicated that both plecanatide 3 mg and 6 mg doses met the primary endpoint and demonstrated statistical significance in the percentage of patients who were overall responders, compared to placebo, during the 12-week treatment period. The company plans to file a Supplement New Drug Application (sNDA) for plecanatide in IBS-C in the first quarter of 2017.

Profitability Valuation

While returns on assets calculated as -146.30% that gives an idea about how efficient management is at using its assets to generate earnings. The firm attains analyst recommendation of 1.70 on scale of 1-5 with week’s performance of -1.27%. Moving toward ratio analysis, it has current ratio of 4.70 and quick ratio was calculated as 4.70. The debt to equity ratio appeared as 6.29 for seeing its liquidity position. The firm attains analyst recommendation of 1.70 out of 1-5 scale with week’s performance of -1.27%.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) need to consider for profitability analysis, in latest session share price swings at $0.51 with percentage change of -2.65%.

The returns on assets were -125.50% that gives an idea about how efficient management is at using its assets to generate earnings. It has returns on equity of -143.40%, which is measuring profitability by disclosing how much profit generates by TNXP with the shareholders’ money.

The firm attains analyst recommendation of 2.50 on scale of 1-5 with week’s performance of -10.34%. The firm current ratio calculated as 11.20, this value is acceptable if it lies in 1.3% to 3%. But its varies industry to industry. To strengthen these views, active industry firm has Quick Ratio of 11.20, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 0, sometimes its remain same with long term debt to equity ratio.

 

About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *